Navigation Links
Carmel Pharma Introduces PhaSeal Secondary Set (C60)
Date:11/1/2009

New Component Streamlines Safe Spiking, Priming and IV Bag Infusion with Hazardous Drugs

Columbus, OH (Vocus) October 31, 2009 -- Carmel Pharma, maker of the PhaSeal System for the safe handling of hazardous drugs, now offers the Secondary Set (C60) for safe, streamlined preparation and administration of IV bag infusions.

For safety and ease of use, the non-vented Secondary Set offers the following features:

 
  • Drip chamber (20 drops/mL)
  • Flow stop to facilitate priming of the Secondary Set from the bag prior to adding the drug
  • Universal spike with built-in PhaSeal Connector for safe, leakproof transfer of the drug to the IV bag
  • DEHP-free PVC tubing (40 in.)

For more information or to order, call 866-487-9250 or visit www.PhaSeal.com.

PhaSeal is more than a system for the safe handling of hazardous drugs. It's the only clinically proven closed-system drug transfer device (CSTD) available today and is validated by more than 10 independent, peer-reviewed, published clinical studies. Distinguished by prominent thought leaders as the "Gold Standard" in safe handling, PhaSeal's airtight Expansion Chamber and leakproof Double Membrane connections prevent exposure to hazardous drugs, including aerosols and vapors, and make it the only system that meets the National Institute for Occupational Safety and Health (NIOSH) and International Society of Oncology Pharmacy Practitioners (ISOPP) definition of a true CSTD. Its
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2

Related medicine news :

1. Carmel Pharma Introduces PhaSeal Secondary Set (C60)
2. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
3. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
4. China Pharma Holdings, Inc. to Report Third Quarter 2009 Financial Results on November 12, 2009
5. Cardinal Health Foundation, The Ohio State University College of Pharmacy Join Forces to Prevent Prescription Medication Abuse
6. WuXi PharmaTech Schedules Third-Quarter 2009 Earnings Release
7. 5 Steps to Pharmaceutical Marketing Happiness
8. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
9. Vestara Awarded MedAssets Supplier Contract For Automated Pharmaceutical Waste Management Solution
10. CVS/pharmacy Rewards Shoppers For Passing on Plastic Bags
11. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Carmel Pharma Introduces PhaSeal Secondary Set (C60) 
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... to impossible, but a new study adds to a ... CT scans may help spot the beginnings of disease ... the greatest risk for lung cancer, 6 percent were ... and follow-up biopsies to confirm the diagnosis. CT scans ...
(Date:5/21/2013)... Sunnyvale, California (PRWEB) May 21, 2013 ... invites individuals who are grieving to remember and honor ... an Evening of Remembrance Memorial Service, Sunday, June 2, ... at Skyline Boulevard, San Mateo, CA 94402. , ... non-denominational, and includes a short program with music, readings ...
(Date:5/21/2013)... Calif. (PRWEB) May 21, 2013 Not ... a dual diagnosis of Borderline Personality Disorder (BPD) and ... is proving to be successful for the treatment of ... 1, Alina Gorgorian, Ph.D., clinical director of Clearview ... in Los Angeles, will provide attendees of the West ...
(Date:5/21/2013)... more likely than their normal-weight counterparts to repeatedly ... continuity of care and leads to more emergency ... The practice of "doctor shopping" among overweight patients ... the health care system, whether that be off-putting ... by providers, or improperly sized medical equipment and ...
(Date:5/21/2013)... N.C. An attack on glioblastoma brain tumor cells ... in an early study to establish the proper dose ... treatment, developed at Duke and tested in an ongoing ... cells have an abundance of receptors that work like ... the cells. , The investigational therapy, known as ...
Breaking Medicine News(10 mins):Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 2Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 3Health News:Hospice Offers Evening of Remembrance Memorial Service in San Mateo, California 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 3Health News:'Doctor shopping' by obese patients negatively affects health 2Health News:'Doctor shopping' by obese patients negatively affects health 3Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2
... makers debate what levels of ozone in the air are ... that the inhaled pollutant impairs the bodys first line of ... as bacteria. , While it has long been known ... pollution, is associated with increased cardiovascular and pulmonary hospitalizations and ...
... Programs in ... Need, BUDAPEST, Hungary, Sept. 29 With more ... each year, it has never,been more critical to increase ... the U.S.-Middle East Partnership for,Breast Cancer Awareness and Research, ...
... finds 123 deaths linked to the products since 1969 ... experts on Friday urged the federal Food and Drug ... and cold medicines for young children. , The recommendation, ... in children under 2, and antihistamines in those younger ...
... MCLEAN, Va., Sept. 28 Sunrise Senior Living,Inc. ... on the status of the independent,investigation being conducted ... Directors, provided an update on management,s Sarbanes-Oxley,Section 404 ... on legal,proceedings. Special Independent Committee Investigation ...
... a,statement by ADA President Kathleen Roth, DDS, on ... Bill: "The American Dental Association applauds the ... in legislation reauthorizing,the State Children,s Health Insurance Program. ... care that they need to enjoy good,oral health. ...
... Medical today announced a,partnership with leading breast care ... including breast care physicians from,Connecticut to California, will ... and availability of an innovative, non-surgical,treatment option for ... will host a gathering of these new Centers ...
Cached Medicine News:Health News:Ozone shuts down early immune response in lungs and body 2Health News:Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries 2Health News:Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries 3Health News:FDA Advisers Urge Ban on Cold Medicines for Young Children 2Health News:FDA Advisers Urge Ban on Cold Medicines for Young Children 3Health News:FDA Advisers Urge Ban on Cold Medicines for Young Children 4Health News:FDA Advisers Urge Ban on Cold Medicines for Young Children 5Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 2Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 3Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 4Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 5Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 6Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 7Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 8Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 9Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 10Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 11Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 12Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 13Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 14Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 15Health News:Statement by ADA President Kathleen Roth, DDS, on the Inclusion of Stable Dental Benefit in SCHIP Reauthorization Bill 2Health News:Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas 2
(Date:5/21/2013)... PARIS and TARRYTOWN, N.Y. ... and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ... Medicine published online the positive Phase 2a study ... asthma.  Dupilumab is an investigational monoclonal antibody targeting the ... which modulates signaling of both IL-4 and IL-13, drivers ...
(Date:5/21/2013)... U.S. spending on specialty prescription drugs — ... cancer, multiple sclerosis and rheumatoid arthritis — is projected ... according to a forecast released today by Express Scripts ... "As we see what,s on the ... act so they can continue to offer an affordable ...
(Date:5/21/2013)... , May 21, 2013  AcelRx ... a specialty pharmaceutical company focused on the ... the treatment of acute and breakthrough pain, ... a placebo-controlled Phase 3 study of its ... System (NanoTab System), the primary efficacy endpoint ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
... 105SL combines enhanced memory, processing ... and reliable all-metal construction. Proven ... and print speed make it ... who value reliability, productivity, consistent ...
... Built on the solid, tested ... six-inch labels --offers an unprecedented level ... placement as well as unique features ... into enterprise systems, automatic calibration, flexible ...
... The 220XiIII quickly prints labels ... at 10 ips. It is ... such as printing chemical drum ... automotive industry labels, banner-sized labels ...
... The 140XiIII is the fastest ... Series. With such powerful performance and ... choice for high-volume, mission-critical applications with ... also well-suited for applications in which ...
Medicine Products: